Zynerba Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is a clinical-stage pharmaceutical company that develops cannabinoid treatments for rare psychiatric and neurological conditions. It focuses on patients and conditions that have very few options on the current pharmaceutical market.

There’s optimism in this stock today thanks to positive results surrounding the Zygel Phase 2 study. Zygel is a transdermal cannabidiol gel that has been shown to treat developmental and epileptic encephalopathies. Zygel was previously reported as having unexpected adverse effects on patients. However, Zynerba investors have now learned that the adverse effects were not unusual for the sample group trialing the medication. The company is now moving towards a Phase 3 trial, which it will plan with the FDA in the first half of 2020.

Zygel could drive revenue in the coming years, and if it passes Phase 3, it could become the most important product in Zynerba portfolio.

Investors who are interested in pharmaceutical cannabis stocks should consider this pick. Momentum in the stock is growing today, yet it remains affordable for smaller alternative portfolios. The average target price of $21.50 suggests a strong upside for investors who buy this month.

Key Data:

  • 1 Year Price Growth: 73%
  • YTD Price Growth: 18%
  • 3 Month Price Growth: -42.65%

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.